Effect of sildenafil on renin secretion in human subjects.
Sildenafil is a potent and selective inhibitor of the cyclic GMP-specific phosphodiesterase (PDE5) that is very effective in the treatment of male impotence. It inhibits breakdown of cyclic guanosine monophosphate (cGMP) formed in penile smooth muscle cells in response to stimulation by nitric oxide resulting in muscle relaxation. PDE5 is widely distributed in the body, being present in the vasculature, platelets, and kidneys. In the kidney, PDE5 is involved in the regulation of sodium excretion and renin secretion. The aim of the present investigation was to investigate the effect of sildenafil, in doses used clinically, on renin secretion in human subjects. The studies were performed in two groups of healthy normotensive subjects: one in which sodium intake was unrestricted, and one in which sodium intake was restricted to 600 mg/day. Blood pressure and heart rate were monitored throughout the study, and blood samples for the measurement of plasma cGMP and cAMP concentrations and plasma renin activity (PRA) were collected. After control measurements, the subjects ingested a capsule containing sildenafil or placebo. Cardiovascular measurements and blood sampling continued for the next 120 min. Sildenafil had only minor cardiovascular effects. Diastolic pressure tended to be lower and heart rate was generally higher after sildenafil than after placebo, but the differences were small. Sildenafil caused a prompt and sustained increase in plasma cGMP concentration and a more gradual increase in plasma cAMP concentration. After the subjects received placebo, there was a progressive decrease in PRA during the 2-hr observation period, presumably reflecting the circadian rhythm in renin secretion. In contrast, PRA failed to decrease after the subjects received sildenafil, thus indicating that sildenafil exerts a stimulatory action on renin secretion. This action on renin secretion may help explain why sildenafil only has minor effect on blood pressure despite the widespread distribution of PDE5 in vascular tissues.
Chiu
Yeong Jen
YJ
Y.J. Chiu General Hospital, Kaohsiung, Taiwan.
Reid
Ian A
IA
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D000242:Cyclic AMP / Q000097:blood; D006152:Cyclic GMP / Q000097:blood*; D004039:Diet, Sodium-Restricted; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*; D011687:Purines; D012016:Reference Values; D012083:Renin / Q000097:blood / Q000378:metabolism*; D015290:Second Messenger Systems / Q000187:drug effects*; D000068677:Sildenafil Citrate; D012982:Sodium, Dietary / Q000008:administration & dosage*; D013450:Sulfones
D004791:Enzyme Inhibitors; D010879:Piperazines; D011687:Purines; D012982:Sodium, Dietary; D013450:Sulfones; D000068677:Sildenafil Citrate; D000242:Cyclic AMP; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D012083:Renin; D006152:Cyclic GMP